SIGA TECHNOLOGIES INC SIGA
SIGA Technologies, Inc. is referred to throughout this report as "SIGA," "the Company," "we" or "us."
We are a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® ("oral TPOXX®," also known as "tecovirimat," "Tecovirimat-SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S. Government and international governments (including government affiliated entities). In certain international markets, the Company may sell TPOXX® through a distributor. Additionally, the Company sells the intravenous formulation of TPOXX® ("IV TPOXX®") to the U.S. Government.
TPOXX® is an antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018, the United States Food & Drug Administration ("FDA") approved the oral formulation of TPOXX® for the treatment of smallpox. The Company has been delivering oral TPOXX® to the U.S. Strategic National Stockpile ("Strategic Stockpile") since 2013.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.6M | $138.7M | $139.9M | $110.8M | $133.7M | $125.0M | $26.7M | $477.1M | $12.3M | $15.0M |
| Cost of revenue | $29.7M | $31.3M | $17.8M | $10.4M | $16.6M | $14.8M | $1.8M | $95.3M | $0 | $0 |
| Gross profit | $64.9M | $107.4M | $122.1M | $100.3M | $117.1M | $110.2M | $25.0M | $381.8M | $12.3M | $15.0M |
| R&D | $20.0M | $12.3M | $16.4M | $22.5M | $9.9M | $10.9M | $13.3M | $13.0M | $16.7M | $19.7M |
| SG&A | $21.2M | $25.1M | $22.0M | $35.1M | $18.0M | $14.7M | $13.3M | $12.9M | $12.3M | $13.7M |
| Total operating expenses | $70.9M | $68.7M | $56.3M | $68.1M | $44.6M | $40.5M | $29.1M | $122.0M | $31.1M | $46.0M |
| Operating income | $23.7M | $70.0M | $83.6M | $42.7M | $89.1M | $84.5M | -$2.3M | $355.1M | -$18.8M | -$31.0M |
| Interest expense | — | — | — | $0 | $0 | $3.0M | $15.8M | $15.5M | $14.8M | $2.4M |
| Pre-tax income | $30.4M | $76.1M | $87.8M | $44.1M | $89.3M | $73.5M | -$10.2M | $411.6M | -$38.3M | -$39.7M |
| Income tax | $7.1M | $16.9M | $19.7M | $10.2M | $19.9M | $17.2M | $2.9M | $10.2M | $2.1M | $13.9K |
| Net income | $23.3M | $59.2M | $68.1M | $33.9M | $69.5M | $56.3M | -$7.2M | $421.8M | -$36.2M | -$39.7M |
| EPS, basic | 0.33 | 0.83 | 0.95 | 0.46 | 0.92 | 0.71 | -0.09 | 5.28 | -0.46 | -0.69 |
| EPS, diluted | 0.32 | 0.82 | 0.95 | 0.46 | 0.91 | 0.71 | -0.15 | 5.18 | -0.46 | -0.69 |
| Shares, diluted (wtd. avg.) | $71.9M | $71.9M | $71.7M | $73.5M | $76.4M | $79.4M | $82.2M | $82.7M | $78.9M | $57.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $155.0M | $155.4M | $150.1M | $98.8M | $103.1M | $117.9M | $65.2M | $100.7M | $19.9M | $28.7M |
| Receivables | $3.3M | $21.2M | $21.1M | $45.4M | $83.7M | $3.3M | $4.2M | $2.0M | $1.8M | $3.2M |
| Inventory | $49.1M | $49.6M | $64.2M | $39.3M | $19.5M | $20.3M | $9.7M | $2.9M | $3.0M | $26.2M |
| Total current assets | $212.9M | $231.0M | $239.0M | $185.8M | $208.8M | $143.6M | $180.0M | $121.3M | $37.4M | $69.2M |
| Property, plant and equipment | $1.1M | $1.3M | $1.3M | $1.8M | $2.4M | $2.1M | $2.6M | $171.3K | $138.6K | $299.5K |
| Goodwill | $898.3K | $898.3K | $898.3K | $898.3K | $898.3K | $898.3K | $898.3K | $898.3K | $898.3K | $898.3K |
| Total assets | $219.5M | $244.3M | $254.4M | $195.0M | $214.7M | $149.8M | $198.6M | $203.4M | $144.7M | $161.0M |
| Accounts payable | $824.5K | $1.3M | $1.5M | $3.4M | $2.0M | $1.3M | $3.1M | $1.7M | $1.3M | $2.5M |
| Short-term debt | — | — | — | — | — | $0 | $80.0M | $0 | — | — |
| Total current liabilities | $18.0M | $25.3M | $54.1M | $21.5M | $30.5M | $10.5M | $91.7M | $11.3M | $6.8M | $7.1M |
| Total liabilities | $20.6M | $28.5M | $57.5M | $24.9M | $40.4M | $20.0M | $100.8M | $100.5M | $467.8M | $448.4M |
| Retained earnings | -$43.1M | -$22.8M | -$38.9M | -$63.8M | -$51.8M | -$95.2M | -$123.0M | -$115.8M | $200.0K | -$501.1M |
| Total equity | $198.8M | $215.8M | $196.9M | $170.2M | $174.3M | $129.8M | $97.8M | $102.9M | -$323.1M | -$287.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $43.5M | $48.8M | $94.8M | $41.6M | $11.5M | $71.5M | -$18.2M | $68.9M | -$18.4M | -$116.8M |
| Depreciation and amortisation | $562.6K | $538.4K | $538.3K | $517.6K | $522.4K | $529.8K | $527.0K | $69.6K | $132.2K | $174.3K |
| Stock-based compensation | $3.7M | $3.6M | $2.1M | $1.8M | $1.3M | $1.4M | $2.1M | $2.3M | $1.1M | $775.5K |
| Capital expenditure | $355.0K | $42.5K | $21.7K | $0 | $50.6K | $15.5K | $29.1K | $102.3K | $100.1K | $23.9K |
| Investing cash flow | -$355.0K | -$42.5K | -$21.7K | $0 | -$50.6K | -$15.5K | -$29.1K | $78.2M | -$100.1K | $1.2M |
| Financing cash flow | -$43.6M | -$43.5M | -$43.4M | -$46.0M | -$26.2M | -$114.6M | -$1.2M | -$3.8M | -$585.6K | $59.1M |
| Dividends paid | $43.1M | $42.7M | $32.1M | $32.9M | $0 | $0 | — | — | — | — |
| Buybacks | $0 | $0 | $11.1M | $13.0M | $26.0M | $28.5M | $0 | $0 | $84.0K | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017421.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |